Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof
The protein known as six-transmembrane epithelial antigen of prostate 2 (STEAP2) is highly expressed in prostate cancer and is associated with the expression of other prostate cancer-associated genes. The present invention provides novel full-length human IgG antibodies that bind to human STEAP2 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both STEAP2 and CD3 and activate T cells via the CD3 complex in the presence of STEAP2-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds human STEAP2. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing STEAP2. The bispecific antigen-binding molecules of the invention are useful for the treatment of prostate diseases and disorders in which an upregulated or induced STEAP2-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of prostate cancers, including castrate-resistant prostate cancer. The present invention also includes anti-STEAP2 antibody drug conjugates which inhibit tumor growth in vivo.
1. An antibody-drug conjugate (ADC) comprising an anti-STEAP2 antibody or antigen-binding fragment thereof and a cytotoxic agent, wherein the antibody or antigen-binding fragment and the cytotoxic agent are covalently attached via a linker, and wherein the anti-STEAP2 antibody or antigen-binding fragment comprises: (a) the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 74, 82, 90, 98, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314, 330, 346, 362, and 378; and (b) the CDRs of a light chain variable region (LCVR) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 306, 322, 338, 354, 370, and 386.
2. The ADC of claim 1 , wherein the anti-STEAP2 antibody or antigen-binding fragment thereof is internalized by human STEAP2-expressing cells.
3. The ADC of claim 2 , wherein the anti-STEAP2 antibody is fully human.
4. The ADC of claim 1 , wherein the anti-STEAP2 antibody or antigen-binding fragment comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of: SEQ ID NOs: 2/10; 18/26; 34/42; 50/58; 66/58; 74/58; 82/58; 90/58; 98/58; 106/114; 122/130; 138/146; 154/162; 170/178; 186/194; 202/210; 218/226; 234/242; 250/258; 266/274; 282/290; 298/306; 314/322; 330/338; 346/354; 362/370; and 378/386.
5. The ADC of claim 4 , wherein the anti-STEAP2 antibody or antigen-binding fragment comprises HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 domains comprising the amino acid sequences, respectively, selected from the group consisting of: SEQ ID NOs:4-6-8-12-14-16; 20-22-24-28-30-32; 36-38-40-44-46-48; 52-54-56-60-62-64; 68-70-72-60-62-64; 76-78-80-60-62-64; 84-86-88-60-62-64; 92-94-96-60-62-64; 100-102-104-60-62-64; 108-110-112-116-118-120; 124-126-128-132-134-136; 140-142-144-148-150-152; 156-158-160-164-166-168; 172-174-176-180-182-184; 188-190-192-196-198-200; 204-206-208-212-214-216; 220-222-224-228-230-232; 236-238-240-244-246-248; 252-254-256-260-262-264; 268-270-272-276-278-280; 284-286-288-292-294-296; 300-302-304-308-310-312; 316-318-320-324-326-328; 332-334-336-340-342-344; 348-350-352-356-358-360; 364-366-368-372-374-376; and 380-382-384-388-390-392.
6. The ADC of claim 1 , wherein the anti-STEAP2 antibody or antigen-binding fragment comprises: (a) a heavy chain variable region (HCVR) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 74, 82, 90, 98, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314, 330, 346, 362, and 378; and (b) a light chain variable region (LCVR) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 10; 26; 42; 58; 114; 130; 146; 162; 178; 194; 210; 226, 242; 258; 274; 290; 306; 322; 338; 354; 370; and 386.
7. The ADC of claim 6 , wherein the anti-STEAP2 antibody or antigen-binding fragment comprises a HCVR/LCVR amino acid sequence pair selected from the group consisting of: SEQ ID NOs: 2/10; 18/26; 34/42; 50/58; 66/58; 74/58; 82/58; 90/58; 98/58; 106/114; 122/130; 138/146; 154/162; 170/178; 186/194; 202/210; 218/226; 234/242; 250/258; 266/274; 282/290; 298/306; 314/322; 330/338; 346/354; 362/370; and 378/386.
8. The ADC of claim 1 , wherein the cytotoxic agent is selected from an auristatin, a maytansinoid, a tubulysin, a tomaymycin, or a dolastatin.
9. The ADC of claim 1 , wherein the cytotoxic agent is an auristatin selected from MMAE or MMAF, or a maytansinoid selected from DM1 or DM4.
10. The ADC of claim 1 , wherein the cytotoxic agent is a maytansinoid having the structure of:
wherein A is arylene or heteroarylene; or
wherein:
A 3a is an amino acid, a peptide having 2-20 amino acids, an alkyl, an alkynyl, an alkenyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, —CR 5 R 6 —, —O—, —C(═O)—, —O—C(═O)—, —C(═O)—O—, —O—C(═O)—O—, —C(═O)—(CH x ) p1 —, —C(═O)—O—(CH x ) p1 —, —(CH x ) p1 —C(═O)—, —(CH x ) p1 —C(═O)—O—, —(O—(CH 2 ) p2 —) p3 —, —((CH 2 ) p2 —O—) p3 —, —C(═S)—, —C(═S)—S—, —C(═S)—NH—, —S—C(═S)—, —S—C(═S)—S—, —S—, —SO—, —SO 2 —, —NR 4 —, —N(R 4 )—C(═O)—N(R 8 )—, —N(R 4 )—C(═O)O—, —N(R 4 )—C(═O)—, —C(═O)—N(R 4 )—, —C(═O)—N(R 4 )—C(═O)—, or —O—C(═O)—NR 4 —, wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted; and
p1, p2 and p3 are each independently 0, or an integer from 1 to 100;
x is 0, 1 or 2;
R 4 , R 5 , R 6 and R 8 are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl; and
R 4a is a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl.
11. The ADC of claim 10 , wherein the maytansinoid is:
12. The ADC of claim 10 , wherein the maytansinoid is:
13. The ADC of claim 1 , comprising an anti-STEAP2 antibody or fragment thereof, and
wherein
is a bond to the anti-STEAP2 antibody or fragment thereof.
14. The ADC of claim 1 , comprising an anti-STEAP2 antibody or fragment thereof, and
wherein
is a bond to the anti-STEAP2 antibody or fragment thereof.
15. The ADC of claim 1 , comprising an anti-STEAP2 antibody or fragment thereof, and
wherein
is a bond to the anti-STEAP2 antibody or fragment thereof.
16. The ADC of claim 13 , wherein the bond contacts the antibody or fragment thereof via a sulfur constituent of a cysteine residue.
17. The ADC of claim 1 , comprising an anti-STEAP2 antibody or fragment thereof, and
or
a mixture thereof,
wherein
is a bond to the anti-STEAP2 antibody or fragment thereof.
18. The ADC of claim 17 , wherein the bond contacts the antibody or fragment thereof via a nitrogen constituent of a lysine residue.
19. The ADC of claim 1 , wherein the ADC comprises 1 to 4 cytotoxic agents per anti-STEAP2 antibody or fragment thereof.
20. A pharmaceutical composition comprising the antibody-drug conjugate of claim 1 , and a pharmaceutically acceptable carrier or diluent.
21. A method for treating a cancer in a subject, the method comprising administering to the subject the pharmaceutical composition of claim 20 .
22. The ADC of claim 10 , wherein the maytansinoid is:
23. The ADC of claim 1 , wherein the anti-STEAP2 antibody or antigen-binding fragment comprises HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 domains, respectively, comprising the amino acid sequences of SEQ ID NOs: 220-222-224-228-230-232.
24. The ADC of claim 1 , wherein the anti-STEAP2 antibody or antigen-binding fragment comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 218, and a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 226.
25. The ADC of claim 1 , wherein the anti-STEAP2 antibody or antigen-binding fragment comprises the CDRs of a HCVR comprising the amino acid sequence of SEQ ID NO: 218, and the CDRs of a LCVR comprising the amino acid sequence of SEQ ID NO: 226.
26. The ADC of claim 23 , wherein the cytotoxic agent is selected from an auristatin, a maytansinoid, a tubulysin, a tomaymycin, or a dolastatin.
27. The ADC of claim 23 , wherein the cytotoxic agent is an auristatin selected from MMAE or MMAF, or a maytansinoid selected from DM1 or DM4.
28. A pharmaceutical composition comprising the antibody-drug conjugate of claim 23 , and a pharmaceutically acceptable carrier or diluent.
29. A method for treating a cancer in a subject, the method comprising administering to the subject the pharmaceutical composition of claim 28 .
30. The ADC of claim 24 , wherein the cytotoxic agent is selected from an auristatin, a maytansinoid, a tubulysin, a tomaymycin, or a dolastatin.
31. The ADC of claim 24 , wherein the cytotoxic agent is an auristatin selected from MMAE or MMAF, or a maytansinoid selected from DM1 or DM4.
32. A pharmaceutical composition comprising the antibody-drug conjugate of claim 24 , and a pharmaceutically acceptable carrier or diluent.
33. A method for treating a cancer in a subject, the method comprising administering to the subject the pharmaceutical composition of claim 32 .
34. The ADC of claim 23 , wherein the cytotoxic agent is:
35. The ADC of claim 23 , wherein the cytotoxic agent is:
36. The ADC of claim 23 , wherein the anti-STEAP2 antibody or antigen-binding fragment is conjugated to:
wherein
is a bond to the anti-STEAP2 antibody or fragment thereof.
37. The ADC of claim 23 , wherein the anti-STEAP2 antibody or antigen-binding fragment is conjugated to:
wherein
is a bond to the anti-STEAP2 antibody or fragment thereof.
38. The ADC of claim 24 , wherein the cytotoxic agent is:
39. The ADC of claim 24 , wherein the cytotoxic agent is:
40. The ADC of claim 24 , wherein the anti-STEAP2 antibody or antigen-binding fragment is conjugated to:
wherein
is a bond to the anti-STEAP2 antibody or fragment thereof.
41. The ADC of claim 24 , wherein the anti-STEAP2 antibody or antigen-binding fragment is conjugated to:
wherein
is a bond to the anti-STEAP2 antibody or fragment thereof.